Inhaled corticosteroids are well-established anti-inflammatory therapies for the prophylactic treatment of asthma, and are recommended in national treatment guidelines as first-line therapy in persistent asthma (1) . Beclomethasone dipropionate has been in use for almost 30 years as an inhaled asthma medication (2) . In the 1990s, fluticasone propionate (FP) and budesonide, with more potent anti-inflammatory effects than beclomethasone dipropionate, were introduced and remain the drugs of first choice (3, 4) . In general, anti-inflammatory effects of corticosteroids are well recognized to depend on the classic steroid receptors (5) . Their effects involve a complex process, including ligand-receptor binding in the cytosol, targeted gene expression, and protein synthesis, so that hours may pass before the onset of hormone actions (6) . This is called the genomic mechanism. However, several lines of evidence have demonstrated that sex steroids and xenoestrogens also exert their effects via nongenomic mechanisms, which are acute in onset and require membrane steroidal receptors without the involvement of nuclear steroid receptors and gene expression (6) . The rapid interaction leads to changes in the kinetics of ion channels such as K 1 channels (7, 8) , L-type Ca 21 channels (9, 10), and Cl 2 channels (11, 12) in various kinds of cells. Despite the evidence, however, less attention has been paid to the acute effects of inhaled corticosteroids on ion channels and transporters. Because steroids are applied directly to the apical side of the respiratory tract, higher concentrations of the drugs on the airway surface are supposed to be achieved than with intravenous application. It is generally established that anion transport mediated through the cystic fibrosis transmembrane conductance regulator (CFTR) anion channel is important in the formation of low-viscosity mucus, thereby maintaining a conductive and aseptic environment in the lung (13) . Indeed, dysfunction of the CFTR, as seen in patients with cystic fibrosis, results in the production of thick mucus plugs and consequently causes serious respiratory damage (13) . Thus, a potential strategy to combat airway obstructive diseases has involved exploring the pharmacological agents that up-regulate CFTR-mediated ion transport. In the present study, we focused especially on the nongenomic effects of inhaled corticosteroids on anion secretion in human airway epithelial cells.
MATERIALS AND METHODS

Chemicals
Forskolin, nystatin, 4,49-dinitrostilbene-2,29-disulfonic acid (DNDS), 59-nitro-2-(3-phenylpropylamino)benzoate (NPPB), and 9-tetrahydro-2-furyl-adenine (SQ22536) were obtained from Sigma-Aldrich Co. (St. Louis, MO). Bumetanide and N-[2-(p-bromocinnamylamino) ethyl]-5-isoquinolinesulfonamide (H89) were purchased from Biomol International, LP (Plymouth Meeting, PA). FP and budesonide were products of Tocris Bioscience, Inc. (Ellisville, MO).
Cell Culture
Calu-3 human airway cells (American Type Culture Collection, Manassas, VA) were grown in a 1:1 mixture of Dulbecco's Modified Eagle's Medium and Ham's F-12 (Invitrogen, Carlsbad, CA) containing 10% FBS (Invitrogen), 100 mg/ml streptomycin, and 100 U/ml penicillin (Invitrogen). The cells were maintained in tissue-culture flasks (T75) at 37 8 C in a humidified 95% air-5% CO 2 incubator. After reaching 80 to 90% confluence, cells were detached using a solution of PBS, 0.04% EDTA, and 0.25% trypsin. The collected cells were seeded onto Snapwell inserts (Costar, Cambridge, MA) at a density of 10 6 cells/well. The inserts had been collagen-coated overnight with 0.2% human placental collagen Type VI (Sigma-Aldrich). The day after seeding the cells on the filters, the medium remaining on the apical side was removed to establish an air interface (14) . The cells were fed by replacement of the basolateral medium every 48 hours. Experiments were performed after 7 to 13 days in culture (see additional details in the online supplement).
Bioelectric Measurements
Calu-3 cells were grown on Snapwell inserts, and were mounted in Ussing chambers filled with physiological saline solution containing 115 mM NaCl, 5 mM KCl, 1 mM MgCl 2 2 mM CaCl 2 , 10 mM glucose, 10 mM HEPES, and 25 mM NaHCO 3 , whose pH was adjusted to 7.4 when gassed with a mixture of 95% O 2 -5% CO 2 at 37 8 C for shortcircuit current (I SC ) measurements, as previously described (15) . I SC changes were measured under voltage clamp conditions, using a voltage clamp amplifier (VCC MC2; Physiologic Instruments, San Diego, CA). A 2-mV pulse of 0.5-second duration was imposed every 20 seconds to calculate resistance by Ohm's law.
Apical membrane Cl 2 currents (I Cl ) in the apical-to-basolateral Cl 2 concentration gradient were estimated after permeabilization of the basolateral membrane with nystatin (100 mM), as previously described (15) (16) (17) . The I Cl reflects Cl 2 permeability through the CFTR (18, 19) . The Cl 2 concentration gradient was established by replacing NaCl with equimolar Na-gluconate in the basolateral solution. In this basolateral solution, CaCl 2 was increased to 4 mM to compensate for the Ca
21
-chelating capacity of the gluconate (16) .
Cyclic AMP Assay
Cellular cAMP was measured using an ELISA-based detection kit, as previously described (20) . Briefly, cells grown on 60-mm dishes (z 7 3 10 6 cells/dish) were stimulated with FP, budesonide (BUD), forskolin, or vehicle. The cells were then lysed in 0.1 N HCl for 20 to 30 minutes after treatment with these agents, and cAMP was measured. We determined the cytosolic cyclic AMP concentration [cAMP] i in the samples according to the manufacturer's instructions.
Analysis of Results
Numerical data are presented as means 6 SD. Statistical differences were determined by the Student t test for comparisons of data between two groups, or one-way ANOVA for multiple group comparisons. P , 0.05 was considered statistically significant.
RESULTS
Effects of Fluticasone Propionate on Airway Anion Transport
The basal I SC and transepithelial resistance in our experiments using Calu-3 cells were 11.7 6 4.7 mA/cm 2 and 350.4 6 80.1 Vcm 2 , respectively (n ¼ 84). The cell monolayer immediately responded to the application of FP (100 mM) from the apical aspect, generating sustained I SC ( Figure 1A) . The difference between the maximum and basal I SC (DI SC ) was 9.2 6 1.3 mA/cm 2 (n ¼ 5). The fluticasone propionate-induced anion secretion was reduced by the application of NPPB (100 mM), a Cl 2 channel blocker: the NPPB-sensitive component was 13.6 6 2.8 mA/cm 2 (n ¼ 5, P , 0.01), in comparison to that without FP (5.2 6 0.9 mA/cm 2 , n ¼ 5; Figure 1B ). To confirm the validity of 100 mM FP, we cumulatively added various concentrations of FP at intervals of approximately 5-10 minutes, because FP-induced I SC responses reach a sustained state by 10 minutes, with the result that the DI SC was increased in a concentration-dependent manner. The concentration for the half-maximal effect was 61.9 6 1.5 mM (n ¼ 4; Figure 1C ).
Compared with the I SC responses of the control sample to FP (Figure 2A ), those in the presence of cAMP-related inhibitors (Figures 2B and 2C) were significantly suppressed. Namely, the FP-induced I SC (ΔI SC ¼ 9.0 6 2.0 mA/cm 2 , n ¼ 5) was reduced to 2.1 6 1.0 mA/cm 2 (n ¼ 5, P , 0.01) and 0.8 6 0.5 mA/cm 2 (n ¼ 5, P , 0.01) by the presence of the protein kinase A (PKA) inhibitor H89 (10 mM) and the adenylate cyclase inhibitor SQ22536 (100 mM), respectively ( Figure 2D ).
Effects of Fluticasone Propionate on Apical and Basolateral Anion Transporters
Anion secretion in Calu-3 cells is the product of coordinated activities of anion transporters on the apical and basolateral membranes (16) . In the cells, basolateral anion uptake is regulated by several anion transporters, including the bumetanide-sensitive Na (21), the DNDS-sensitive Na 1 -2HCO 3 2 cotransporter NBC1 (22) , and the DNDS-sensitive HCO 3 2 /Cl 2 exchanger AE2 (23). The HCO 3 2 and Cl 2 taken up by the cells commonly pass through the CFTR, a cAMP-regulated anion channel, in Calu-3 cells (16) . Because basolateral anion entry is generally the rate-limiting step for transepithelial anion transport (24), we estimated the functions of basolateral anion transporters by measuring bumetanide (50 mM)-sensitive and DNDS (2 mM)-sensitive components in the FP-induced I SC . As shown in Figure  3A , both components comprise the FP-induced I SC ( Figure 3A) . Compared with the control sample, the former and latter components were increased, from 0.9 6 0.7 mA/cm 2 (n ¼ 6) and 1.0 6 0.2 mA/cm 2 (n ¼ 6) to 5.0 6 1.5 mA/cm 2 (n ¼ 6, P , 0.01) and 4.6 6 1.1 mA/cm 2 (n ¼ 6, P , 0.01), respectively ( Figures 3B  and 3C ). On the other hand, apical Cl 2 export was estimated as I Cl in the nystatin-permeabilized monolayer in Figures 3D and 3E. Correlated with I SC changes, the application of FP (100 mM) caused the development of an inward I Cl (ΔI Cl ¼ 11.6 6 4.5 mA/cm 2 at 20 minutes after its addition, n ¼ 6; Figures 3D and 3F ). The increases in the FP-induced I Cl were counteracted by pretreatment with NPPB (100 mM), inhibitors of CFTR (ΔI Cl ¼ 1.5 6 0.9 mA/cm 2 , n ¼ 6, P , 0.01; Figures 3E and 3F ). Bioelectric Interactions between FP and Forskolin-Stimulated Responses cAMP-related stimuli are well-known to generate I SC augmentations that reflect electrogenic anion transport. Indeed, the application of forskolin (10 mM, an adenylate cyclase activator; Figure 4A ) to the basolateral face led to a rapid increase in I SC , followed by a sustained component that is inhibited by bumetanide and DNDS. Figure 4B shows that the forskolin-induced increases in I SC were attenuated by the presence of FP (100 mM). The forskolin-induced I SC increases (ΔI SC ) were diminished from 52.5 6 5.0 mA/cm 2 (n ¼ 6) to 20.3 6 4.3 mA/cm 2 (n ¼ 6, P , 0.01) in the peak component, and from 21.9 6 3.0 mA/cm 2 (n ¼ 6) to 8.7 6 2.4 mA/cm 2 (n ¼ 6, P , 0.01) in the sustained component when both of them were estimated as increases from the I SC concentrations just before the application of forskolin. When they are estimated as increases from basal I SC concentrations before the application of FP, however, the sustained ΔI SC values in the absence of FP were not significantly different from those in its presence (Figures 4B; ΔI SC ¼ 19.3 6 4.9 mA/cm 2 ). Indeed, the bumetanide-sensitive and DNDSsensitive components (7.9 6 2.3 mA/cm 2 and 8.4 6 2.0 mA/cm 2 , n ¼ 6, respectively) in the sustained I SC in the experiments shown in Figure 4A were not significantly different from those in the experiments shown in Figure 4B (7.6 6 1.9 mA/cm 2 and 9.0 6 1.7 mA/cm 2 , n ¼ 6, respectively). In the nystatin-permeabilized monolayer used for the estimation of apical Cl 2 conductance, FP-induced I Cl increases under the forskolin-stimulated condition were markedly suppressed (2.1 6 0.7 mA/cm 2 , n ¼ 6; Figure 4C ), compared with those under the forskolin-unstimulated condition (11.2 6 3.8 mA/cm 2 , n ¼ 6; Figure 4D ). In the presence of FP (100 mM; Figure 4D ), the I Cl increases attributable to the application of forskolin were attenuated. The forskolin-induced I Cl increases (ΔI Cl ) were suppressed to 10.6 6 2.3 mA/cm 2 (n ¼ 6, P , 0.01), compared with those in the absence of FP (21.0 6 5.0 mA/cm 2 , n ¼ 6). However, the values were not significantly different from total I Cl developments attributable to the combination of FP and forskolin that were estimated as increases from basal concentrations (21.9 6 4.2 mA/cm 2 , n ¼ 6). Figure 5A shows representative traces of BUD (100 mM)-induced I SC (ΔI SC ¼ 6.2 6 2.8 mA/cm 2 , n ¼ 5). Like the effects of FP, the bumetanide-sensitive and DNDS-sensitive I SC (0.9 6 0.3 mA/cm 2 , n ¼ 5, and 1.0 6 0.5 mA/cm 2 , n ¼ 5, respectively) were significantly increased to 2.8 6 1.0 mA/cm 2 (n ¼ 5) and 3.5 6 1.2 mA/cm 2 (n ¼ 5, P , 0.01), respectively, by the application of BUD ( Figures 5B and 5C ). Apical Cl 2 export was estimated as I Cl in the nystatin-permeabilized monolayer in Figures 5D and  5E . Under the forskolin-unstimulated condition, the application of BUD (100 mM) caused the development of an inward I Cl (ΔI Cl ¼ 6.1 6 2.2 mA/cm 2 , n ¼ 4; Figure 5D ). Compared with the response, BUD-induced I Cl increases under the forskolinstimulated condition were markedly suppressed (ΔI Cl ¼ 1.9 6 0.7 mA/cm 2 , n ¼ 4, P , 0.05; Figure 5E ).
BUD Reproduced the Effects of Fluticasone Propionate
Effects of FP and BUD on Cytosolic cAMP Concentrations
In the cytosolic cAMP assay (Figure 6 
DISCUSSION
The local delivery of inhaled corticosteroids may yield considerably higher concentrations on the airway surface. FP is considered to be slowly absorbed over a long period of time after deposition in the lungs (25) . The total lung deposition of radiolabeled FP administered with a metered dose inhaler has been shown to range from 10-36% (22% 6 9%) in adults (26) . To determine the average concentration of a drug on the airway surface after its deposition, it is necessary to know the volume of the airway surface liquid. Widdicombe (27) estimated that the liquid volumes are 1.0 ml for the trachea and bronchi, and 2.6 ml for the conducting bronchioles. Combining these lines of information indicates that inhaling FP (molecular weight, 500.57) at 800 mg (1.6 mmol) by mouth would result in the average concentration on the airway surface as follows: airway surface FP ¼ 1.6 mmol 3 0.22 (% lung deposition)/(1.0 1 2.6) ml ¼ 98 mM. However, the deposition of inhaled FP in the airways is uneven (28), and FP is predominantly deposited in the proximal respiratory tract (29) . Based on this conjecture, we applied FP at 100 mM to the airway epithelial cells, resulting in immediate rises of I SC , followed by sustained currents. The FP-induced responses were inhibited by the presence of NPPB (a Cl 2 channel blocker), bumetanide (an inhibitor of the NKCC1 Na
cotransporter), or DNDS (an inhibitor of the NBC1/AE2 HCO 3 2 -dependent anion transporter), suggesting that the FP-induced responses are composed of anion secretion. The concentration for the half-maximal effect was approximately 60 mM, which is possibly within the range of the clinically used concentration.
In general, cAMP/PKA is a key molecule for anion secretion in any polarized epithelial cell, including Calu-3 submucosal gland cells (30) . In the present study, we showed that the FP-induced I SC were significantly reduced by the presence of inhibitors of PKA and adenylate cyclase. We also found that FP stimulated I Cl , reflecting activation of the cAMP-dependent Cl 2 channel CFTR, which is the exclusive gate for Cl 2 export in Calu-3 cells (18) . These results indicate that the nongenomic effects of FP, at least in part, involve cAMP-dependent cascades to stimulate gland secretion.
As shown in our additional data (see Figure E1 in the online supplement), however, FP-induced Cl 2 secretion was not evoked in normal human bronchial epithelial cells, which show Na 1 absorption but much less CFTR-mediated Cl 2 secretion. Moreover, Na 1 absorption was not affected by FP in the cells. Thus, FP may exert its nongenomic effects on gland secretion in particular, to enhance mucociliary clearance in the respiratory tract.
As shown in the present study, the forskolin-induced and FP-induced I SC were composed of rapid increases and subsequent sustained increases, as demonstrated in previous studies using cAMP-related agents (16, 31) . Especially in the forskolininduced responses, the sustained levels were much lower than the initial peak points ( Figure 4A ). However, the peak components were not detected in the changes of apical membrane Cl 2 conductance in the nystatin-permeabilized monolayer ( Figure  4C ). In general, cAMP-dependent anion secretion is characterized not only by apical CFTR activation, but also by the parallel activation of NKCC1 and NBC1/AE2 anion transporters (15, 20) Thus, it is conceivable that (1) the initial phase is produced by a gush of anions that had accumulated in the cells beforehand, and (2) the sustained phase is maintained by the function of basolateral anion transporters such as NKCC1, NBC1, and AE2. During anion transport, however, the cAMP-dependent In the former groups, the measurements were performed 30 minutes after the addition of fluticasone dipropionate (FP, 100 mM), budesonide (BUD, 100 mM), and or its vehicle (0.05% DMSO, control). In the latter, the monolayer was exposed to FK for 20 minutes after a 30-minute pretreatment with FP or BUD. Data represent means 6 SD (n ¼ 6). *P , 0.01 and y P , 0.01 indicate significant differences from the values of FK-unstimulated (shown as "control") and FK-stimulated control groups (shown as "FK"), respectively. regulation of NKCC1 is indirect and is attributable to the secondary effects of cAMP on changes in cell volume, the cytoskeleton, and intracellular Cl 2 concentrations, leading to the regulation of various kinases, including protein kinase C (32, 33) .
We also showed that stimulation by FP failed to enhance the I SC and I Cl responses to forskolin, namely, (1) bumetanidesensitive and DNDS-sensitive components in the forskolinstimulated I SC were not significantly increased by the presence of FP, and (2) forskolin-induced I Cl was less up-regulated by FP. These observations suggest that FP and forskolin share elements of a common signaling pathway for the activation of CFTR, NKCC1, NBC1, and AE2.
In the cytosolic cAMP assay, however, we found that FP synergistically increased [cAMP] i in combination with forskolin. Similar results were obtained by using a combination of FP and the b-adrenergic receptor (b 2 -AR) agonist salmeterol, which are currently used as a standard combination therapy for patients with asthma (see Figure E2 in the online supplement). Thus, FP is likely to exert its effects on adenylate cyclase without competing with the conventional pathway for the activation of adenylate cyclase by means of forskolin or b 2 -AR stimulation. However, our results of no significant effects of FP on [cAMP] i in the absence of forskolin do not necessarily negate the involvement of cAMP in the effects of FP. A signaling pathway to activate an apical adenylate cyclase closely associated with CFTR in Calu-3 cells has been proposed (34) . Like the inhaled corticosteroids, cAMP/PKA-related agents such as phosphodiesterase inhibitors and adenosine also stimulate Cl 2 secretion in the setting of very low or often undetectable [cAMP]i concentrations (31, 35) . In general, these observations have been also interpreted as the results of compartmentalized changes in cAMP concentrations in the subcellular region (34, 36) .
In the present study, we demonstrated that BUD reproduced the effects of FP on I SC , I Cl , and [cAMP] i . Beclomethasone dipropionate also potentiated [cAMP] i in the presence of forskolin, and it caused similar but smaller effects in I SC (data not shown). This suggests that the nongenomic effects of inhaled corticosteroids share a common mechanism.
In Calu-3 cells, cAMP stimulation induces the parallel activation of NKCC1 and NBC1/AE2, as did FP and BUD, whereas Ca 21 -mediated stimuli generate the selective up-regulation of NKCC1 (15, 16, 20, 37) . Although the Ca 21 -induced Cl 2 secretion is inhibited by charybdotoxin, a selective KCNN4 Ca 21 -activated K 1 channel blocker (30), neither FP-induced nor BUD-induced responses were sensitive to charybdotoxin (data not shown). This indicates less of a contribution of Ca 21 -mediated mechanisms to the nongenomic effects of FP and BUD.
Taken together, inhaled corticosteroids such as FP and BUD stimulate CFTR-mediated anion transport through adenylatecyclase-mediated mechanisms in a nongenomic fashion, thus sharing elements of a common signaling pathway for the activation of cAMP-activated anion transporters (e.g., CFTR) with other cAMP-related stimuli. However, the combination of corticosteroids with forskolin induces the synergistic production of cAMP, suggesting that corticosteroids and forskolin have different target sites on adenylate cyclase. Figure 7 constitutes a schematic drawing of the hypothetical mechanism, taking the effects of FP on the CFTR as an example. Likewise, the combination of FP and a b 2 -AR agonist salmeterol synergistically increases cytosolic cAMP concentrations. Thus, FP/salmeterol combination therapies, which are currently used for bronchial asthma and chronic obstructive pulmonary disease, may comprise more rational treatments than previously thought. The nongenomic effects of these agents may involve therapeutic aspects for mucus congestive airway diseases, in addition to their genomic effects that are generally recognized. The effects of FP on AC synergistically enhanced cAMP production, in combination with these cAMP-related agents. FP exerts its effect on AC without competing with the conventional pathway for AC activation.
